Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05786222 · ClinicalTrials.gov registry record · NA
Permanent Supportive Housing Overdose Prevention
A NA study, sponsored by NYU Langone Health.
- Active
- Registry status
- NA
- Development phase
- 1,350
- Enrollment target
NCT05786222: Active NA study, sponsored by NYU Langone Health.
NCT05786222 is a NA study that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 1,350 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05786222, a NA study, is active but no longer recruiting, sponsored by NYU Langone Health.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,350 participants
- Enrollment target
Study Summary
Permanent supportive housing (PSH), the gold standard intervention for ending chronic homelessness, has expanded rapidly across the U.S. in recent years. Due to a confluence of individual and environmental risk factors, PSH tenants face heightened risk for overdose. While evidence-based practices to prevent overdose exist, they have not been broadly implemented in PSH settings. This study will address this research to practice gap by studying the implementation of evidence-based practices to prevent overdose in 20 PSH buildings in New York. In a community-partnered stepped wedge randomized controlled trial, the investigators will study a package of implementation strategies that includes an implementation toolkit, tenant and staff implementation champions, limited practice facilitation, and learning collaboratives. Outcomes will be examined using surveys and qualitative interviews with PSH tenants and staff; observation; and analysis of Medicaid claims data.
Primary Outcome
Buildings will receive a fidelity checklist score of 0 (not implemented), 1 (partial implementation), or 2 (full implementation) for each overdose prevention practice. The primary outcome is total summed score, with higher scores indicating greater fidelity.
Interventions
- BEHAVIORAL CSH-Delivered Overdose Prevention Support
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,350 participants |
| Start Date | 2023-09-26 |
| Est. Completion | 2027-01-31 |
| Phase | NA |
What the registry record for NCT05786222 still lists
NCT05786222 is an interventional study that assigns participants to a tested intervention. Its 1,350 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which CSH-Delivered Overdose Prevention Support is the first listed.
NCT05786222 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05786222 about?
NCT05786222 is a clinical study titled "Permanent Supportive Housing Overdose Prevention". Permanent supportive housing (PSH), the gold standard intervention for ending chronic homelessness, has expanded rapidly across the U.S. in recent years. Due to a confluence of individual and environmental risk factors, PSH tenants face heightened risk for overdose. While evidence-based practices to...
What is the current status of trial NCT05786222?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,350 participants. The study started on 2023-09-26. Estimated completion is 2027-01-31.
What interventions are being tested in trial NCT05786222?
The interventions under investigation include: CSH-Delivered Overdose Prevention Support (BEHAVIORAL).
Who is sponsoring clinical trial NCT05786222?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05786222's enrollment target sits among peer trials
1,350 73rd of 2000 higher than 1,927 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06318169 · 1,350 participants · Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- NCT06605404 · 1,350 participants
Pan-tumor MRD Study
- NCT06806163 · 1,350 participants · NA
Machine-Learning Prediction and Reducing Overdoses With EHR Nudges
- NCT06731608 · 1,344 participants · NA
OsteoPorotic fracTure preventION System (OPTIONS) Research Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI